In October, Teva completed the acquisition of Cephalon for a total consideration of $6.15 billion in cash, as per data compiled by Bloomberg. Pursuant to the acquisition, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.Teva foresees realizing annual cost synergies of at least $500 million within three years of the transaction's closing. Non-GAAP diluted earnings per share for full year 2011 are estimated in the range of $4.92 to $5.02, including non-GAAP diluted earnings per share contribution of approximately 15 cents from the consolidation of the Cephalon acquisition. The acquisition is seen supporting Teva's long-term strategy of achieving more than $9 billion revenue in 2015, as compared to $4.6 billion in 2010. Of the 36 analysts covering the stock, 75% rate it a buy. On average, analysts polled by Bloomberg expect the stock to gain 29% to $53.77 in the coming 12 months. >>To see these stocks in action, visit the 8 Big Acquirers of 2011 portfolio on Stockpickr.